TY - JOUR A1 - Liaqat, Anam A1 - Sednev, Maksim V. A1 - Stiller, Carina A1 - Höbartner, Claudia T1 - RNA-cleaving deoxyribozymes differentiate methylated cytidine isomers in RNA JF - Angewandte Chemie International Edition N2 - Deoxyribozymes are emerging as modification-specific endonucleases for the analysis of epigenetic RNA modifications. Here, we report RNA-cleaving deoxyribozymes that differentially respond to the presence of natural methylated cytidines, 3-methylcytidine (m\(^3\)C), N\(^4\)-methylcytidine (m\(^4\)C), and 5-methylcytidine (m\(^5\)C), respectively. Using in vitro selection, we found several DNA catalysts, which are selectively activated by only one of the three cytidine isomers, and display 10- to 30-fold accelerated cleavage of their target m\(^3\)C-, m\(^4\)C- or m\(^5\)C-modified RNA. An additional deoxyribozyme is strongly inhibited by any of the three methylcytidines, but effectively cleaves unmodified RNA. The mXC-detecting deoxyribozymes are programmable for the interrogation of natural RNAs of interest, as demonstrated for human mitochondrial tRNAs containing known m\(^3\)C and m\(^5\)C sites. The results underline the potential of synthetic functional DNA to shape highly selective active sites. KW - organic chemistry KW - site-specific RNA cleavage KW - deoxyribozymes KW - epitranscriptomics KW - in vitro selection KW - RNA modification Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-256519 VL - 60 ER - TY - JOUR A1 - Liaqat, Anam A1 - Sednev, Maksim V. A1 - Stiller, Carina A1 - Höbartner, Claudia T1 - RNA-Cleaving Deoxyribozymes Differentiate Methylated Cytidine Isomers in RNA JF - Angewandte Chemie International Edition N2 - Deoxyribozymes are emerging as modification-specific endonucleases for the analysis of epigenetic RNA modifications. Here, we report RNA-cleaving deoxyribozymes that differentially respond to the presence of natural methylated cytidines, 3-methylcytidine (m\(^3\)C), N\(^4\)-methylcytidine (m\(^4\)C), and 5-methylcytidine (m\(^5\)C), respectively. Using in vitro selection, we found several DNA catalysts, which are selectively activated by only one of the three cytidine isomers, and display 10- to 30-fold accelerated cleavage of their target m\(^3\)C-, m\(^4\)C- or m\(^5\)C-modified RNA. An additional deoxyribozyme is strongly inhibited by any of the three methylcytidines, but effectively cleaves unmodified RNA. The m\(^X\)C-detecting deoxyribozymes are programmable for the interrogation of natural RNAs of interest, as demonstrated for human mitochondrial tRNAs containing known m\(^3\)C and m\(^5\)C sites. The results underline the potential of synthetic functional DNA to shape highly selective active sites. KW - Deoxyribozymes KW - Epitranscriptomics KW - RNA Modification KW - Site-Specific RNA Cleavage KW - in vitro Selection Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-254544 VL - 60 IS - 35 ER - TY - JOUR A1 - Kokic, Goran A1 - Hillen, Hauke S. A1 - Tegunov, Dimitry A1 - Dienermann, Christian A1 - Seitz, Florian A1 - Schmitzova, Jana A1 - Farnung, Lucas A1 - Siewert, Aaron A1 - Höbartner, Claudia A1 - Cramer, Patrick T1 - Mechanism of SARS-CoV-2 polymerase stalling by remdesivir JF - Nature Communications N2 - Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls. Here we use synthetic RNA chemistry, biochemistry and cryoelectron microscopy to establish the molecular mechanism of remdesivir-induced RdRp stalling. We show that addition of the fourth nucleotide following remdesivir incorporation into the RNA product is impaired by a barrier to further RNA translocation. This translocation barrier causes retention of the RNA 3ʹ-nucleotide in the substrate-binding site of the RdRp and interferes with entry of the next nucleoside triphosphate, thereby stalling RdRp. In the structure of the remdesivir-stalled state, the 3ʹ-nucleotide of the RNA product is matched and located with the template base in the active center, and this may impair proofreading by the viral 3ʹ-exonuclease. These mechanistic insights should facilitate the quest for improved antivirals that target coronavirus replication. KW - SARS-CoV-2 polymerase KW - Remdesivir KW - RNA-dependent RNA polymerase KW - Molecular mechanism KW - Biochemistry KW - Cryoelectron microscopy KW - RNA Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-220979 VL - 12 ER - TY - JOUR A1 - Mieczkowski, Mateusz A1 - Steinmetzger, Christian A1 - Bessi, Irene A1 - Lenz, Ann-Kathrin A1 - Schmiedel, Alexander A1 - Holzapfel, Marco A1 - Lambert, Christoph A1 - Pena, Vladimir A1 - Höbartner, Claudia T1 - Large Stokes shift fluorescence activation in an RNA aptamer by intermolecular proton transfer to guanine JF - Nature Communications N2 - Fluorogenic RNA aptamers are synthetic functional RNAs that specifically bind and activate conditional fluorophores. The Chili RNA aptamer mimics large Stokes shift fluorescent proteins and exhibits high affinity for 3,5-dimethoxy-4-hydroxybenzylidene imidazolone (DMHBI) derivatives to elicit green or red fluorescence emission. Here, we elucidate the structural and mechanistic basis of fluorescence activation by crystallography and time-resolved optical spectroscopy. Two co-crystal structures of the Chili RNA with positively charged DMHBO+ and DMHBI+ ligands revealed a G-quadruplex and a trans-sugar-sugar edge G:G base pair that immobilize the ligand by π-π stacking. A Watson-Crick G:C base pair in the fluorophore binding site establishes a short hydrogen bond between the N7 of guanine and the phenolic OH of the ligand. Ultrafast excited state proton transfer (ESPT) from the neutral chromophore to the RNA was found with a time constant of 130 fs and revealed the mode of action of the large Stokes shift fluorogenic RNA aptamer. KW - Fluorogenic RNA Aptamers KW - Synthetic Functional RNAs KW - Chili RNA Aptamer KW - Co-Crystal Structures of Chili RNA KW - RNA KW - Optical Spectroscopy KW - Structural Biology KW - X-ray Crystallography Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-254527 VL - 12 ER - TY - JOUR A1 - Kabinger, Florian A1 - Stiller, Carina A1 - Schmitzová, Jana A1 - Dienemann, Christian A1 - Kokic, Goran A1 - Hillen, Hauke S. A1 - Höbartner, Claudia A1 - Cramer, Patrick T1 - Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis JF - Nature Structural & Molecular Biology N2 - Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA mutations and impairs SARS-CoV-2 replication in animal models and in humans. Here, we establish the molecular mechanisms underlying molnupiravir-induced RNA mutagenesis by the viral RNA-dependent RNA polymerase (RdRp). Biochemical assays show that the RdRp uses the active form of molnupiravir, β-d-\(N^4\)-hydroxycytidine (NHC) triphosphate, as a substrate instead of cytidine triphosphate or uridine triphosphate. When the RdRp uses the resulting RNA as a template, NHC directs incorporation of either G or A, leading to mutated RNA products. Structural analysis of RdRp–RNA complexes that contain mutagenesis products shows that NHC can form stable base pairs with either G or A in the RdRp active center, explaining how the polymerase escapes proofreading and synthesizes mutated RNA. This two-step mutagenesis mechanism probably applies to various viral polymerases and can explain the broad-spectrum antiviral activity of molnupiravir. KW - Molnupiravir KW - RNA-Dependent RNA Polymerase KW - SARS-CoV2 Replication Impairment KW - Molnupiravir-Induced RNA Mutagenesis Mechanism KW - Cryoelectron Microscopy Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-254603 VL - 28 ER -